Skip to content

Effects of probiotic administration in the elderly

Efficacy of administration of Probiotics in institutionalized elderly

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
REBEC
Registry ID
RBR-3dmq83
Enrollment
Unknown
Registered
2018-06-25
Start date
2017-07-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, unspecified

Interventions

Intake of probiotic Bifidobacterium longum (at a concentration of 10 to 9) and placebo, daily, for 10 weeks. 30 elderly in the placebo group received placebo via oral (capsule with starch)
30 elderly of the treated group received a probiotic capsule Bifidobacterium longum, orally.
Biological/vaccine
G07.203.300.456.500

Sponsors

Universidade Federal do Rio Grande do Norte
Lead Sponsor
Universidade Federal do Rio Grande do Norte
Collaborator

Eligibility

Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: - To be 60 years or more; being institutionalized; obtain values between 10 and 24 in the Mini Mental State Examination (MMSE), to exclude individuals with very mild dementias and very severe dementias; be able to walk

Exclusion criteria

Exclusion criteria: -Be less than 60 years; not being institutionalized; obtain value less than 10 and greater than 24 in the Mini Mental State Examination (MMSE); not being able to walk

Design outcomes

Primary

MeasureTime frame
Decrease of at least 10% in the concentration of some metabolites related to chronic subclinical inflammation, variation observed in the pre and post intervention measurements, verified using the Nuclear Magnetic Resonance method and analysis using Chenomx software.

Secondary

MeasureTime frame
Cognitive assessment performed through the "Mini mental state examination", "Rey auditory-verbal learning test (RAVLT)",   and "Wechsler Adult Intelligence Scale - Revised (WAIS-R)" have not, so far, had a significant difference between pre- and post-treatment. Analyzes are still being done.

Countries

Brazil

Contacts

Public ContactKenio de Lima

Universidade Federal do Rio Grande do Norte

limke@uol.com.br+55-084 3215-4100

Outcome results

None listed

Source: REBEC (via WHO ICTRP)